Corixa Overview
- Year Founded
-
1994
- Status
-
Acquired/Merged
- Employees
-
263
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$300M
Corixa General Information
Description
Developer of immunotherapeutics. The company develops immunotherapeutics to combat autoimmune diseases, infectious diseases and cancer.
Contact Information
Website
www.corixa.comCorporate Office
- 1900 9Th Avenue
- Suite 1100
- Seattle, WA 98101
- United States
Corporate Office
- 1900 9Th Avenue
- Suite 1100
- Seattle, WA 98101
- United States
Corixa Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 29-Apr-2005 | $300M | Completed | Generating Revenue | ||
| 7. Grant | 06-Jan-2004 | Completed | Generating Revenue | |||
| 6. PIPE | 24-Jun-2003 | Completed | Generating Revenue | |||
| 5. PIPE | 19-Aug-2002 | Completed | Generating Revenue | |||
| 4. Grant | 12-Aug-2002 | Completed | Generating Revenue | |||
| 3. Grant | 01-Nov-2000 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 10-May-1996 | $5M | $20.3M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 02-Dec-1994 | $15.3M | $15.3M | Completed | Startup |
Corixa Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Corixa Patents
Corixa Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240350410-A1 | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof | Pending | 16-Aug-2021 | ||
| US-20240115688-A1 | Novel antigens | Pending | 02-Dec-2020 | ||
| US-20230234992-A1 | Modified betacoronavirus spike proteins | Inactive | 05-Jun-2020 | ||
| US-11278613-B2 | Lyssavirus antigen constructs | Inactive | 17-Jul-2017 | ||
| US-20200222526-A1 | Lyssavirus antigen constructs | Active | 17-Jul-2017 | A61K39/205 |
Corixa Signals
Corixa Former Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Axiom Venture Partners | Venture Capital | Minority | ||
| Costanoa Ventures | Venture Capital | Minority | ||
| Forward Ventures | Venture Capital | Minority | ||
| Frazier Healthcare Partners | PE/Buyout | Minority | ||
| InterWest Health Partners | Corporate Venture Capital | Minority |
Corixa Investments & Acquisitions (3)
Corixa’s most recent deal was a Merger/Acquisition with Coulter Pharmaceutical for . The deal was made on 16-Oct-2000.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Coulter Pharmaceutical | 16-Oct-2000 | Merger/Acquisition | Biotechnology | ||
| ImmGenics Pharmaceuticals | 01-Nov-1998 | Corporate | Drug Discovery | ||
| GenQuest | 16-Sep-1998 | Merger/Acquisition | Biotechnology |
Corixa FAQs
-
When was Corixa founded?
Corixa was founded in 1994.
-
Where is Corixa headquartered?
Corixa is headquartered in Seattle, WA.
-
What is the size of Corixa?
Corixa has 263 total employees.
-
What industry is Corixa in?
Corixa’s primary industry is Biotechnology.
-
Is Corixa a private or public company?
Corixa is a Private company.
-
What is the current valuation of Corixa?
The current valuation of Corixa is .
-
What is Corixa’s current revenue?
The current revenue for Corixa is .
-
How much funding has Corixa raised over time?
Corixa has raised $195M.
-
Who are Corixa’s investors?
Axiom Venture Partners, Costanoa Ventures, Forward Ventures, Frazier Healthcare Partners, and InterWest Health Partners are 5 of 18 investors who have invested in Corixa.
-
When was Corixa acquired?
Corixa was acquired on 29-Apr-2005.
-
Who acquired Corixa?
Corixa was acquired by GSK.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process